Method of detecting a biomarker for Huntington's disease in a subject, wherein the method comprises the step of detecting the biomarker for Huntington's disease, wherein the biomarker for Huntington's disease is mutant huntingtin, and wherein the biomarker for Huntington's disease is detected in a tear fluid sample obtained from the subject.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The invention describes benzene-1,3,5-tricarboxamide (BTA) based hydrogels. The hydrogels have purpose in tissue culturing for in vitro applications such as drug screening or in vivo applications such as transplantation. The hydrogels are particularly tough but still allow 3D printing and cell culturing. The invention further describes 3D printing of the hydrogels and uses of the hydrogels.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
C07C 69/76 - Esters d'acides carboxyliques dont un groupe carboxyle estérifié est lié à un atome de carbone d'un cycle aromatique à six chaînons
C07C 205/57 - Composés contenant des groupes nitro liés à un squelette carboné le squelette carboné étant substitué de plus par des groupes carboxyle ayant des groupes nitro et des groupes carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné
C07D 207/46 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec les hétéro-atomes liés directement à l'atome d'azote du cycle
C08G 65/00 - Composés macromoléculaires obtenus par des réactions créant une liaison éther dans la chaîne principale de la macromolécule
The invention relates to use of a polymer (I) as a precursor of a shape-memory polymer, wherein the polymer (I) comprises a backbone which is end-capped by a crosslinkable end-capping unit comprising a moiety having a crosslinkable functionality, wherein the backbone comprises a copolymer of a cyclic carbonate selected from the group consisting of trimethylene carbonate, ethylene carbonate, propylene carbonate, styrene carbonate and glycerol carbonate and a comonomer selected from the group consisting of ε- caprolactone, α-acetolactone, β-propiolactone, γ-butyrolactone, δ- valerolactone, β-butyrolactone, γ-caprolactone, γ-octalactone, γ-nonalactone, δ- decalactone, γ-decalactone, ω-pentadecalactone, diglycolic anhydride, glycolide,lactide, norcamphor lactone, verbanone lactone, dihydrocarvide, wherein the lactone is unsubstituted or substituted by halogen or C1-C12 alkyl, and combinations thereof.
The present invention relates to an immunoprotective type implantable cell delivery device for implanting cells in a subject comprising an enclosed space between a top and bottom porous membrane and a mesh. The mesh is used to prevent clustering of the cells. The invention further relates to a method of constructing the closed type implantable cell delivery device. The invention also relates to the device for use in a method of treatment.
The invention relates to an in vitro method for the preparation of a culture of pre-implantation and post-implantation embryo-like three-dimensional cell aggregates, the method comprising several stages of induction and differentiation with particular cell culture media. The invention also provides induction cell culture media and a system for the high throughput analysis and imaging of embryo-like cell aggregates.
C12N 5/073 - Cellules ou tissus embryonnairesCellules fœtales ou tissus fœtaux
6.
A SENSING DEVICE FOR DETECTING AN ANALYTE IN A LIQUID SAMPLE MEDIUM, A PREPARATION APPARATUS FOR PREPARING AN ANALYTE CONTAINING LIQUID SAMPLE MEDIUM FOR USE IN SUCH SENSING DEVICE, A METHOD FOR FORMING SUCH SENSING DEVICE AND A METHOD FOR DETECTING AN ANALYTE IN A SAMPLE OF AIR, IN PARTICULAR IN A SAMPLE OF RESPIRATORY AIR USING SUCH SENSING DEVICE
The present disclosure relates to a sensing device (100) for detecting an analyte in a liquid sample medium (50). Additionally, the disclosure also pertains to a preparation apparatus (200) for preparing an analyte containing liquid sample medium (50) for use in such sensing device (100). Furthermore, the present disclosure also pertains to a method for forming such sensing device (100) and a method for detecting an analyte in a sample of air, in particular in a sample of respiratory air using such preparation apparatus (200) and such sensing device (100).
G01N 27/12 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de l'absorption d'un fluideRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de la réaction avec un fluide
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
G01N 33/497 - Analyse physique de matériau biologique de matériau biologique gazeux, p. ex. de l'haleine
The invention describes a method for culturing kidney organoids using a prolonged exposure to FGF9, FGF20 or an activator of FGFR1 and/or FGFR3. The method results in improved kidney morphology in the resulting organoids, in particular the organoids have reduced cartilage induction. The invention further relates to organoids obtained by the method and uses thereof.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
C08G 64/00 - Composés macromoléculaires obtenus par des réactions créant une liaison ester carbonique dans la chaîne principale de la macromolécule
An open type implantable cell delivery device for transplanting cells in a subject, comprising: a bottom film having a surface area with a plurality of pores; a top film having a surface area with a plurality of pores, positioned on top of the bottom film such that the top film substantially covers the bottom film to create an inner space; wherein the bottom film and the top film are formed from a biocompatible biomaterial, and wherein the bottom film comprises a plurality of microwells positioned to face the surface area of the top film with the open sides of said microwells, wherein the pore size of the bottom film and optionally the top film is such that it allows vascularization or vascular ingrowth in the device through the pores.
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
B32B 3/02 - Caractérisés par des caractéristiques de forme en des endroits déterminés, p. ex. au voisinage des bords
B32B 3/26 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes
B32B 3/30 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes caractérisés par une couche comportant des retraits ou des saillies, p. ex. des gorges, des nervures
B32B 7/05 - Liaison entre couches les couches n’étant pas liées sur toute la surface, p. ex. liaison discontinue ou par motifs particuliers
B32B 27/08 - Produits stratifiés composés essentiellement de résine synthétique comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique d'une résine synthétique d'une sorte différente
B32B 27/30 - Produits stratifiés composés essentiellement de résine synthétique comprenant une résine vinyliqueProduits stratifiés composés essentiellement de résine synthétique comprenant une résine acrylique
B32B 27/36 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyesters
10.
MEANS AND METHODS FOR THE TREATMENT OF CALCIUM CRYSTAL DEPOSITION DISEASES
The invention is in the field of medical treatments, in particular the treatment of humans, more in particular humans with calcium deposition diseases. In one aspect, the invention provides polypeptides that prevent or decrease the precipitation of calcium crystals in the human body, also known as ectopic calcification. More in particular, the invention relates to a circular polypeptide consisting of an amino acid sequence according to SEQ ID NO: 1, wherein the amino acids are D-amino acids, pharmaceutical compositions comprising a polypeptide as described herein and their use in the treatment of a disease selected from the group consisting of osteoarthritis, frozen shoulder syndrome, heterotopic ossification, vascular calcification, kidney stones and calcinosis.
The implantable ocular drainage device is configured for controlling intraocular pressure in the eye. The ocular implantable drainage device comprises a wall body surrounding in an endless manner a reservoir with a reservoir volume defined by means of the wall body, wherein the device further comprises at least one fluid inlet, at least one fluid outlet for filling the reservoir with fluid and at least one fluid flow channel providing fluid communication between the at least one fluid inlet and the at least one fluid outlet.
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
12.
METHODS FOR SELECTING CULTURED CORNEAL ENDOTHELIAL CELLS
The present invention provides a method for determining the quality of cultured corneal endothelial cells (CECs) comprising measuring in or on a cultured CEC a level of expression of the genes Thrombospondin-2 (THBS2) and/or Vitelline Membrane Outer Layer 1 Homolog (VMO1), and determining that the quality of said cultured CEC is non-therapy-grade if said measured level of expression corresponds to a THBS2+ and/or VMO1+ expression profile.
A COMPUTER IMPLEMENTED METHOD AND AN APPARATUS FOR NON-INVASIVE AND EXTRA-CORPORALLY DETERMINING THE ARTERIAL CONCENTRATION OF A RADIOPHARMACEUTICAL, IN PARTICULAR A RADIOTRACER IN AN ORGAN OF AN ANIMAL AND/OR HUMAN BODY.
The present disclosure relates to a technique to non-invasively and extra-corporeally measure the arterial concentration of a radiotracer administered to animal and/or human bodies or subjects with a radiation detector. In particular a computer implemented method for non-invasive and extra-corporally determining the arterial concentration of a radiopharmaceutical, for example a radiotracer, in an organ of an animal and/or human body is proposed, the computer implemented method comprising the steps of: i) receiving, from the moment of administration of a certain amount of the radiopharmaceutical in the animal and/or human body, by one or more radiation sensors positioned near or on a measurement location of an organ electromagnetic radiation emitted by the radiopharmaceutical over time; ii) converting the received electromagnetic radiation in a time-sequence of radiation signals; iii) generating one or more time-frequency representations of the radiation signals by time-frequency transformation, and iv) analyzing the time-frequency representations for determining the arterial concentration of the radiopharmaceutical.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
14.
METHOD OF AND APPARATUS FOR VITRIFYING AQUEOUS SAMPLES
The invention relates to a method of and apparatus for vitrifying an aqueous sample. The method comprises the steps of providing a sample held by a sample carrier (3), regulating the temperature in a confined space (6) to a temperature above the ice nucleation temperature of the sample, guiding the sample through the confined space (6) containing the gas at the regulated temperature and positioning the sample in line with at least one nozzle (10) for a cryogenic liquid, which at least one nozzle (10) is located in the confined space (6) or outside the confined space (6), where the sample is maintained above the ice nucleation temperature of the sample, and vitrifying the sample by jetting a cryogenic liquid from the at least one nozzle (10) and onto the sample.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
15.
A METHOD FOR OPERATING A MICROFLUIDIC DEVICE, A MICROFLUIDIC DEVICE AND A BIOREACTOR SYSTEM
The invention relates to a method for operating a microfluidic device comprising a base provided with a chamber configured to receive at least one microfluidic component, and a sealing member provided with fluid passages configured to communicate with the chamber. The invention further relates to a microfluidic device provided with a base provided with a chamber configured to receive at least one microfluidic component, and a sealing member provided with fluid passages configured to communicate with the chamber, wherein the sealing member is connectable to the base from an unconnected position with the base to a connected position with the base providing a leak-free sealed chamber configured for fluid flow by means of the fluid passages of the sealing member and at least one fluid source outside the chamber. The invention also relates to bioreactor system.
The disclosure relates to an implantable ocular drainage device for controlling intraocular pressure (IOP) comprising at least one drainage channel, and at least one magnetic control mechanism. The at least one magnetic control mechanism is a magnetic valve mechanism configured to regulate flow in the at least one drainage channel.
The present invention relates to a method for the detection of analytes in a tissue sample, wherein a combination of mass spectrometry imaging (MSI) analysis and laser capture microdissection (LCM) is carried out on a tissue sample on a conductive glass slide, using the same section for MSI and LCM. The method can be used for the detection of proteins, lipids, metabolites and glycans.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 1/28 - Préparation d'échantillons pour l'analyse
18.
METHOD FOR CONTROLLING SPONTANEOUSLY TRIGGERED MECHANICAL VENTILATION OF A PATIENT
A computer-implemented method for controlling spontaneously triggered mechanical ventilation of a patient, the method comprising: obtaining electrical impedance tomography, EIT, data recorded during a PEEP trial; detecting at least one aerated region among the of lung-related tissue regions in the PEEP trial, based on the obtained EIT data; determining at least one regional peak flow, RPF, corresponding with the at least one aerated region, based on the obtained EIT data; calculating at least one set of regional lung mechanics parameters for the at least one aerated region, based on the at least one RPF; and outputting the at least one set of regional lung mechanics parameters for the at least one aerated region or a parameter derived therefrom, in a format suitable for direct input into a spontaneously triggered mechanical ventilator.
Described herein is a complex of a negatively charged polysaccharide and a protein having serine protease activity. The negatively charged polypeptide can for example be heparin or non-anticoagulant heparin. The serine protease can for example be an elastase or activated protein C. The complex can be used in the treatment, prevention or amelioration of an immunothrombosis related disease or disorder.
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
20.
BIOMARKER FOR PREDICTING THE RESPONSE TO TLR 7-AGONIST IMMUNOTHERAPY OF SQUAMOUS INTRAEPITHELIAL LESIONS AND THERAPEUTIC USE THEREOF
The present invention relates to methods for predicting the response of a subject with a high- grade squamous intraepithelial lesion (HSIL) to toll-like receptor 7 (TLR7) agonist immunotherapy. Specifically, the methods for predicting the response to TLR7 agonist immunotherapy comprises determining, in a pre-immunotherapy tissue sample of the lesion, the count of intraepithelial and/or5 stromal cells that are positive for the biomarkers CD4, CD68 and CD11c, or cells having CD3+CD8- FOXP3-, CD68+CD163- and CD11c+ phenotypes, preferably corrected for cell having a CD3+CD8- FOXP3+ phenotype. The invention further relates to TLR7 agonists for use in immunotherapy HSIL in subjects predicted to complete responders in accordance with the prediction methods of the invention.
The present invention relates to a method for creating a three- dimensional structure for cell growth by creating a template of a polymer, applying a hydrogel support onto the template and removing the template. The present invention further provides a device for cell growth comprising a polymer template embedded in a hydrogel.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
B33Y 80/00 - Produits obtenus par fabrication additive
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
B33Y 40/20 - Posttraitement, p. ex. durcissement, revêtement ou polissage
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
B29C 64/30 - Opérations ou équipements auxiliaires
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
Sthijns, Mireille Maria Johanna Petronella Elisabeth
Troost, Frederik Jan
Muijsenberg, Art
Abrégé
The present invention relates to a compound for use in the regulation of saccharide absorption via the gastrointestinal tract, wherein the compound is selected from the group consisting of hydroxycinnamic acids, curcuminoids and derivatives thereof. The present invention further relates to a composition comprising the compound according to the present invention.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
The present invention relates to compositions and methods for treating and/or preventing heart failure with preserved ejection fraction (HFpEF), especially in subjects with an impaired NO-cGMP-PKG signalling axis. The inventors established that not all patients with clinically defined HFpEF suffer from insufficient NO-cGMP- PKG signalling. In accordance with the invention, patients with an HFpEF diagnosis can be selected/stratified based on biomarkers such as NADPH oxidase Type 5 (Nox5) plasma levels, nitration of tyrosine residues on plasma proteins and/or cell- based assays. Moreover, the inventors have found that treating this signalling network at two or more nodes, especially sGC and NO synthase, achieves the first-in-class mechanism-based, causal and high precision therapy for HFpEF endotype which is defined by insufficient NO-cGMP-PKG signalling.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The invention relates to an object comprising a polymer composition comprising a biodegradable polymer and mitomycin C, wherein i) the object is a mesh of fibers comprising the polymer composition or ii) the object is a multilayer film comprising a first outer layer and a second outer layer and an inner layer provided between and adhered to the first outer layer and the second outer layer, wherein the inner layer comprises the polymer composition and each of the first outer layer and a second outer layer comprises a biodegradable polymer.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The disclosed subject matter is in the field of molecular diagnostics, and in particular provides diagnostic markers, methods, systems, and kits for detecting a predisposition to, or the presence of colorectal cancer (CRC), such as detecting a change in the expression status or methylation status, or a combination thereof of any one or more of a number of genes. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the disclosed methods.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
26.
METHOD FOR THE DIAGNOSIS AND TREATMENT OF ESSENTIAL PRIMARY HYPERTENSION
The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value. Further, the invention also provides theragnostics, wherein diagnosis is combined with therapy, more in particular wherein the (plasma) level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that reverse the result of NOX5 activity in the subject, when the determined NOX5 level is exceeding a predetermined threshold level. Finally, the invention relates to an animal model suitable for developing diagnostic methods and therapeutic treatments for NOX5-dependent hypertension.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
27.
IMMUNOPROTECTIVE TYPE IMPLANTABLE CELL DELIVERY DEVICE
The present invention relates to an immunoprotective type implantable cell delivery device for implanting cells in a subject comprising an enclosed space between a top and bottom porous membrane and a mesh. The mesh is used to prevent clustering of the cells. The invention further relates to a method of constructing the closed type implantable cell delivery device. The invention also relates to the device for use in a method of treatment.
The present invention relates to a method for aiding in the prediction of stroke and/or dementia in a subject, said method comprising a) determining the amount of the biomarker RET (Rearranged during transfection) in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) aiding in the prediction of stroke and/or dementia. The present invention further relates to a method for aiding in the assessment of the extent of white matter lesions in a subject, a method for aiding in the assessment whether a subject has experienced one or more silent strokes and to a method for aiding in the diagnosis of atrial fibrillation in a subject. Further encompassed by the present invention are the corresponding uses.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
29.
Endorectal probe device for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject
The invention relates to the radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. In particular the invention relates to an endorectal probe device for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. Furthermore the invention relates to an afterloading apparatus for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject using an endorectal probe device according to the invention. Moreover the invention relates to a method for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject, wherein the method implements the endorectal probe device according to the invention.
The invention relates to a hydrogel from crosslinked polymers with a defined stiffness. The described hydrogels are particularly useful for growing organoids such as for example kidney organoids. The invention further relates to methods of manufacturing the hydrogels and to methods of culturing organoids, as well as uses of the obtained hydrogels.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C08L 5/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
The invention describes benzene-1,3,5-tricarboxamide (BTA) based hydrogels. The hydrogels have purpose in tissue culturing for in vitro applications such as drug screening or in vivo applications such as transplantation. The hydrogels are particularly tough but still allow 3D printing and cell culturing. The invention further describes 3D printing of the hydrogels and uses of the hydrogels.
The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
33.
USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME
The invention relates to a pharmaceutical composition comprising one or more stimulators of soluble guanylate cyclase (sGC), or a combination of at least one stimulator of sGC and at least one activator of sGC, for use in a method of treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3′,5′-guanosine monophosphate in the patient to be treated. The invention also relates to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator. The invention also relates to a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator, for use in a method for the treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3′,5′-guanosine monophosphate in the patient to be treated. Furthermore, the invention relates to a kit comprising a pharmaceutical composition comprising one or more stimulators of sGC; a pharmaceutical composition comprising one or more stimulators of sGC and one or more activators of sGC; a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator; or to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator.
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
34.
THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA
The present invention relates to a therapeutic combination comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist. More specifically, the invention relates to said therapeutic combination for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury. The invention also relates to a pharmaceutical composition comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist, and to said pharmaceutical composition for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
35.
METHOD AND KIT OF PARTS FOR SURGICAL CORRECTION OF SPINAL DEFORMITIES
A method of affixing a spinal rod to a vertebra and a kit of parts to be used in said method are provided. The method comprises providing a length of tape, which length of tape has a knotted portion tied around a hollow support body in a slidable knot. By passing the ends of the tape underneath the lamina of the vertebra, and subsequently passing the ends of the tape through the hollow support body, the knotted portion of the length of tape may be slid from the hollow support body towards the vertebra. Because the slidable knot is tied onto the hollow support body, chance of errors in the knot may be reduced. The kit of parts provides the hollow support body (202) and the length of tape (104).
A61B 17/70 - Dispositifs de mise en position ou de stabilisation de la colonne vertébrale, p. ex. stabilisateurs comprenant un liquide de remplissage dans un implant
The invention relates to implant devices, particularly the invention relates to scaffolds produced by electrospinning which can be used as implant device either combined with a hydrogel or by itself. The scaffolds have an aligned oriented region and a random oriented region that allows for surgical retention methods. The invention further relates to methods of producing the implants and uses thereof. The invention also relates to custom electrospinning targets for the production of the scaffolds.
An open type implantable cell delivery device for transplanting cells in a subject, comprising: a bottom film having a surface area with a plurality of pores; a top film having a surface area with a plurality of pores, positioned on top of the bottom film such that the top film substantially covers the bottom film to create an inner space;wherein the bottom film and the top film are formed from a biocompatible biomaterial, and wherein the bottom film comprises a plurality of microwells positioned to face the surface area of the top film with the open sides of said microwells, wherein the pore size of the bottom film and optionally the top film is such that it allows vascularization or vascular ingrowth in the device through the pores.
The invention is in the field of medical treatments, in particular the treatment of humans, more in particular humans with calcium deposition diseases. In one aspect, the invention provides polypeptides that prevent or decrease the precipitation of calcium crystals in the human body, also known as ectopic calcification. More in particular, the invention relates to a circular polypeptide consisting of an amino acid sequence according to SEQ ID NO: 1, wherein the amino acids are D-amino acids, pharmaceutical compositions comprising a polypeptide as described herein and their use in the treatment of a disease selected from the group consisting of osteoarthritis, frozen shoulder syndrome, heterotopic ossification, vascular calcification, kidney stones and calcinosis.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
39.
MEANS AND METHODS FOR THE TREATMENT OF CALCIUM CRYSTAL DEPOSITION DISEASES
The invention is in the field of medical treatments, in particular the treatment of humans, more in particular humans with calcium deposition diseases. In one aspect, the invention provides polypeptides that prevent or decrease the precipitation of calcium crystals in the human body, also known as ectopic calcification. More in particular, the invention relates to a circular polypeptide consisting of an amino acid sequence according to SEQ ID NO: 1, wherein the amino acids are D-amino acids, pharmaceutical compositions comprising a polypeptide as described herein and their use in the treatment of a disease selected from the group consisting of osteoarthritis, frozen shoulder syndrome, heterotopic ossification, vascular calcification, kidney stones and calcinosis.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
40.
DIGITAL PATHOLOGY OF BREAST CANCER BASED ON A SINGLE CELL MASS SPECTROMETRY IMAGING DATABASE
The invention relates to methods using an automated system for characterizing or analyzing single cells in a sample based on mass spectrometry imaging. The methods find use in among other in pathology and diagnosis. The invention further relates to a method for constructing a reference database for use herein.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
41.
METHOD OF PERFORMING RADIOMICS ANALYSIS ON IMAGE DATA
The invention is directed at a method of performing radiomics analysis on imaging data from an imaging system. A processing unit receives image data of a part of a body, including a region of interest. For each of a plurality of image features, an image feature parameter value is derived by the processing unit, the value being a quantitative representation of the image feature. Using a signature model, signature model values are derived from image feature parameter values, for performing radiomics analysis. The imaging system comprises a sensor array with sensors for providing sensor signals, and receiving image data comprises retrieving sensor signal data of sensor signals directly from the sensor. The image data is raw data formed by said sensor signal data for performing the radiomics analysis directly on said raw image data, for enabling to provide at least one classification result associated with the region of interest.
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Scientific research, Especially Scientific research in the medical, paramedical and pharmacological fields; Services of chemists and physicists; Medical laboratory services, Bacteriological laboratory services; Expert reports by laboratory technicians. Hospitals.
The invention relates to a system to guide the growth of the spinal column, the system comprising at least one elongated support member and at least one connector comprising a guiding portion having a bearing surface for the elongated support member, a bone connecting portion designed to secure the connector to a vertebra, and between the bone connecting portion and the guiding portion at least one transverse opening extending transversely to the longitudinal center line of the connector.
A61B 17/70 - Dispositifs de mise en position ou de stabilisation de la colonne vertébrale, p. ex. stabilisateurs comprenant un liquide de remplissage dans un implant
44.
IMPLANTABLE OCULAR DRAINAGE DEVICE FOR CONTROLLING INTRAOCULAR PRESSURE
The implantable ocular drainage device for controlling intraocular pressure comprises at least one drainage channel. The at least one drainage channel comprises a section, wherein the section of the at least one drainage channel is configured as a valve mechanism by making this section at least partially from a light responsive liquid crystal polymer.
The invention relates to an implantable ocular drainage device for controlling intraocular pressure (IOP) comprising at least one drainage channel, and at least one magnetic control mechanism. The at least one magnetic control mechanism is a magnetic valve mechanism configured to regulate flow in the at least one drainage channel.
The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value. Further, the invention also provides theragnostics, wherein diagnosis is combined with therapy, more in particular wherein the (plasma) level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that reverse the result of NOX5 activity in the subject, when the determined NOX5 level is exceeding a predetermined threshold level. Finally, the invention relates to an animal model suitable for developing diagnostic methods and therapeutic treatments for NOX5-dependent hypertension.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
47.
METHOD FOR DETECTION OF ANALYTES IN A SINGLE TISSUE SAMPLE FROM ITO SLIDES USING MSI-LCM
The present invention relates to a method for the detection of analytes in a tissue sample, wherein a combination of mass spectrometry imaging (MSI) analysis and laser capture microdissection (LCM) is carried out on a tissue sample on a conductive glass slide, using the same section for MSI and LCM. The method can be used for the detection of proteins, lipids, metabolites and glycans.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 1/04 - Dispositifs pour prélever des échantillons à l'état solide, p. ex. par coupe à l'outil
NEDERLANDSE ORGANISATIE VOOR WETENSCHAPPELIJK ONDERZOEK (NWO) (Pays‑Bas)
Inventeur(s)
Wieringa, Paul Andrew
Moroni, Lorenzo
De La Rosa, Victor Retamero
Hoogenboom, Richard
Abrégé
The present invention relates to a method for creating a three- dimensional structure for cell growth by creating a template of a polymer, applying a hydrogel support onto the template and removing the template. The present invention further provides a device for cell growth comprising a polymer template embedded in a hydrogel.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
The disclosed subject matter is in the field of molecular diagnostics, and in particular provides diagnostic markers, methods, systems, and kits for detecting a predisposition to, or the presence of colorectal cancer (CRC), such as detecting a change in the expression status or methylation status, or a combination thereof of any one or more of a number of genes. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the disclosed methods.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
The present invention relates to a hydrogel comprising an oxidized alginate containing aldehyde groups, wherein the oxidized alginate is crosslinked with an imine type crosslinker. The hydrogel is particularly suitable as a bioink, i.e. for 3D printing of cell structures. The gels provide good printability and exhibit excellent viscoelasticity, shear thinning and self-healing characteristics.
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
B33Y 80/00 - Produits obtenus par fabrication additive
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
The invention relates to a three-dimensional printer head (10) comprising a receiving section (15) having at least two inlets (17,19) for receiving material into the receiving section, wherein the printer head further comprises a dispensing unit (21) for printing a three dimensional product, an extrusion screw (13) at least extending between the receiving section and the dispensing unit for conditioning the material received in the receiving section and for displacing the material to the dispensing unit for dispensing the conditioned material.
The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value. Further, the invention also provides theragnostics, wherein diagnosis is combined with therapy, more in particular wherein the (plasma) level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that reverse the result of NOX5 activity in the subject, when the determined NOX5 level is exceeding a predetermined threshold level. Finally, the invention relates to an animal model suitable for developing diagnostic methods and therapeutic treatments for NOX5-dependent hypertension.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value. Further, the invention also provides theragnostics, wherein diagnosis is combined with therapy, more in particular wherein the (plasma) level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that reverse the result of NOX5 activity in the subject, when the determined NOX5 level is exceeding a predetermined threshold level. Finally, the invention relates to an animal model suitable for developing diagnostic methods and therapeutic treatments for NOX5-dependent hypertension.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The invention is in the field of medical treatments. It provides means and methods for the treatments of diseases related to or caused by neutrophil extracellular traps (NETs). More in particular, it relates to a peptide comprising an amino acid sequence H-CEPLSEVEDYLDSSLKYNAKDTINYC-OH (SEQ ID NO: 1) or an equivalent thereof that differs from SEQ ID NO: 1 by not more than 3 amino acids.
The present invention relates to a method for aiding in the prediction of stroke and/or dementia in a subject, said method comprising a) determining the amount of the biomarker RET (Rearranged during transfection) in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) aiding in the prediction of stroke and/or dementia. The present invention further relates to a method for aiding in the assessment of the extent of white matter lesions in a subject, a method for aiding in the assessment whether a subject has experienced one or more silent strokes and to a method for aiding in the diagnosis of atrial fibrillation in a subject. Further encompassed by the present invention are the corresponding uses.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
57.
QUALITY CONTROL STANDARDS FOR MASS SPECTROMETRY IMAGING
The present invention relates to a method for controlling quality of a mass spectrometry method for detecting one or more target species in a tissue sample. The method in particular relates to a mass spectrometry imaging method. The method uses s 3D bioprinting technique to create a construct on a mass spectrometry slide that can be used as a quality control standard.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
58.
THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA
The present invention relates to a therapeutic combination comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist. More specifically, the invention relates to said therapeutic combination for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia- reperfusion injury. The invention also relates to a pharmaceutical composition comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist, and to said pharmaceutical composition for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/223 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'alpha-amino-acides
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
60.
USE OF A SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR OR OF A COMBINATION OF A SGC STIMULATOR AND AN SGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF SGC IS OXIDIZED OR WHEREIN SGC IS DEFICIENT IN HEME
The invention relates to a pharmaceutical composition comprising one or more stimulators of soluble guanylate cyclase (sGC), or a combination of at least one stimulator of sGC and at least one activator of sGC, for use in a method of treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3',5'-guanosine monophosphate in the patient to be treated. The invention also relates to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator. The invention also relates to a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator, for use in a method for the treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3',5'-guanosine monophosphate in the patient to be treated. Furthermore, the invention relates to a kit comprising a pharmaceutical composition comprising one or more stimulators of sGC; a pharmaceutical composition comprising one or more stimulators of sGC and one or more activators of sGC; a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator; or to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
61.
CIRCULATING SPON-1 (SPONDIN-1) IN THE ASSESSMENT OF ATRIAL FIBRILLATION
The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of SPON-1 in a sample from the subject, and comparing the amount of SPON-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of SPON-1.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
62.
METHOD FOR THE TREATMENT OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY IN NEWBORNS
The invention is in the field of medical treatments. It provides means and methods for treating acute or sub-acute brain injury due to asphyxia in newborns. It has now been found that hypoxic-ischemic encephalopathy may effectively be treated by administering a composition comprising Annexin A1 to a subject in need of such a treatment. The invention therefore relates to a treatment for hypoxic-ischemic encephalopathy in newborns by administering a composition comprising Annexin A1 to a preterm born newborn.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The present invention relates to selective presenilin-2 γ-secretase inhibitors for use in the treatment of various diseases associated with a defect leading to Notch receptor hyperactivity. In particular the present invention relates to selective presenilin-2 γ-secretase inhibitors for use as a highly selective anti-cancer treatment. Preferred selective presenilin-2 γ-secretase inhibitors include small molecules, like 4-aminoquinolines or imidazole compounds, (monoclonal) antibodies and known γ-secretase inhibitors or analogues and combinations thereof.
The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP 10 in a sample from the subject, and comparing the amount of BMP 10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP 10-type peptide in a sample from a subject.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
65.
CIRCULATING DKK3 (DICKKOPF-RELATED PROTEIN 3) IN THE ASSESSMENT OF ATRIAL FIBRILLATION
The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
66.
Device for supporting the testing of a brachytherapy applicator and a method for testing of such a brachytherapy applicator prior to the use of the brachytherapy applicator in brachytherapy radiation treatments
The invention relates to a device for supporting the testing of a brachytherapy applicator prior to the use of the brachytherapy applicator in brachytherapy radiation treatments.
The invention also relates to a method for testing of a brachytherapy applicator prior to the use of the brachytherapy applicator in brachytherapy radiation treatments.
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p. ex. sur la position ou la section du faisceauMesure de la distribution spatiale de radiations
High performance LCP materials Abstract: A liquid crystalline polymer (LCP) comprising at least i) a mesogenic acid residue unit, ii) a non-mesogenic hydroxy acid residue unit, iii) a diacid residue unit, and being chain-extended by a reaction with an oxazoline residue unit comprising at least two oxazoline rings. The invention further pertains to a process to manufacture the LCP, blends of the LCP and a thermoplastic polymer, a process to manufacture the blend and molded bodies comprising the LCP and/or the blend.
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Education, entertainment and sport services; Teaching; Organisation of conferences, seminars and exhibitions for educational purposes; University education services; Educational activities and Arranging for students to participate in educational courses; Publishing, reporting, and writing of texts; Publication of scientific information materials. Science and technology services; Testing, authentication and quality control; Medical and pharmacological research services; Natural science services. Medical examinations; Physical examination services; Providing of information in relation to medicine.
69.
POROUS BIOACTIVE METAL-CALCIUM PHOSPHATE MEDICAL IMPLANT
The present invention relates to a medical implant comprising a porous composite wherein the porous composite contains metal particles, in particular spherical titanium particles and calcium phosphate particles. The invention further relates to a method of making such a medical implant, for instance by means of additive manufacturing. The invention also relates to a composition for making the medical implant.
A61L 27/42 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice inorganique
The invention also relates to a MRI apparatus for obtaining images of a target volume of a human and/or animal subject using magnetic resonance imaging (MRI), said MRI apparatus at least comprising: a housing defining a target area for accommodating said human and/or animal subject; at least one main magnet unit and at least one magnetic gradient unit for applying—during use—one or more magnetic field gradients along three independent orthogonal spatial axes in said target area, as well as at least one radiofrequency (RF) pulse generation unit for applying one or more sets of RF pulses towards said target area; a RF receiving unit for acquiring MRI signals possibly having multi-channel spatially sensitive characteristics; and a computer processing unit for processing said acquired MRI signals and for producing said magnetic resonance image data.
G01V 3/00 - Prospection ou détection électrique ou magnétiqueMesure des caractéristiques du champ magnétique de la terre, p. ex. de la déclinaison ou de la déviation
G01R 33/561 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne par réduction du temps de balayage, c.-à-d. systèmes d'acquisition rapide, p. ex. utilisant des séquences d'impulsions écho-planar
G01R 33/28 - Détails des appareils prévus dans les groupes
G01R 33/483 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p. ex. spectroscopie in vivo
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
G01R 33/565 - Correction de distorsions d'image, p. ex. dues à des inhomogénéités de champ magnétique
The present invention relates to echocardiographic image data processing systems and in particular to echocardiographic image data processing systems arranged for obtaining, transforming, storing and representation of volumetric echocardiographic imaging data. In an aspect, an echocardiography image data processing system is proposed which comprises an image data collecting module, arranged for obtaining echocardiography image data of a subject, the echocardiography image data comprising a discrete time-sequence of three-dimensional echocardiographic images, wherein the echocardiography image data is obtained in a DICOM-ECG format and generated by a DICOM compliant echocardiography acquisition systems;an decoder module, arranged for decoding the DICOM-ECG image data into a series of DICOM attributes comprising at least one DICOM pixel data attribute; an image data conversion engine, arranged for performing a wavelet transformation on the at least one DICOM pixel data attribute into a wavelet representation of the echocardiography image data; and a storage module, arranged for storing the wavelet representation of the echocardiography image data on a storage medium for reproduction of the echocardiography image data of the subject at a predefined refresh rate which is higher than the discrete time-sequence of the three-dimensional echocardiographic images.
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
The present invention relates to a hydrogel comprising an oxidized alginate containing aldehyde groups, wherein the oxidized alginate is crosslinked with an imine type crosslinker. The hydrogel is particularly suitable as a bioink, i.e. for 3D printing of cell structures. The gels provide good printability and exhibit excellent viscoelasticity, shear thinning and self-healing characteristics.
B29C 64/00 - Fabrication additive, c.-à-d. fabrication d’objets en trois dimensions [3D] par dépôt additif, agglomération additive ou stratification additive, p. ex. par impression en 3D, stéréolithographie ou frittage laser sélectif
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
The invention relates to a sample preparation apparatus comprising a vacuum chamber, at least one sample holding unit for holding a sample in the vacuum chamber, and at least one sublimation device arranged in the vacuum chamber at a distance from the at least one sample holding unit, wherein the sublimation device comprises a heat conducting body having at least one receiving section configured to receive a substance to be sublimated and at least one temperature conditioner for heating/cooling the receiving section of the heat conducting body to carry out a sublimation and deposition process on the sample in the vacuum chamber.
B01L 9/00 - Dispositifs de supportDispositifs de serrage
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p. ex. fermetures étanches au videDispositions pour le réglage externe des composants électronoptiques ou ionoptiques
B05D 3/10 - Traitement préalable des surfaces sur lesquelles des liquides ou d'autres matériaux fluides doivent être appliquésTraitement ultérieur des revêtements appliqués, p. ex. traitement intermédiaire d'un revêtement déjà appliqué, pour préparer les applications ultérieures de liquides ou d'autres matériaux fluides par d'autres moyens chimiques
B05D 7/00 - Procédés, autres que le flocage, spécialement adaptés pour appliquer des liquides ou d'autres matériaux fluides, à des surfaces particulières, ou pour appliquer des liquides ou d'autres matériaux fluides particuliers
B05D 1/00 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces
Disclosed is a method for diagnosing paroxysmal atrial fibrillation in a subject, involving: determining the amount of FABP-3 (Fatty acid binding protein 3) in a sample from a subject suspected to suffer from paroxysmal atrial fibrillation, and comparing the determined amount to a reference amount. The method may further involve the determination of a BNP-type peptide. Also disclosed is a device adapted to carry out the method.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The invention relates to a three-dimensional printer head (10) comprising a receiving section (15) having at least two inlets (17,19) for receiving material into the receiving section, wherein the printer head further comprises a dispensing unit (21) for printing a three dimensional product, an extrusion screw (13) at least extending between the receiving section and the dispensing unit for conditioning the material received in the receiving section and for displacing the material to the dispensing unit for dispensing the conditioned material.
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
The present invention relates to selective presenilin-2 γ-secretase inhibitors for use in the treatment of various diseases associated with a defect leading to Notch receptor hyperactivity. In particular the present invention relates to selective presenilin-2 γ-secretase inhibitors for use as a highly selective anti-cancer treatment. Preferred selective presenilin-2 γ-secretase inhibitors include small molecules, like 4- aminoquinolines or imidazole compounds, (monoclonal) antibodies and known γ-secretase inhibitors or analogues and combinations thereof.
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to a process for post treatment of shaped polyamide articles. The process comprises exposing the articles to water having a 1H NMR Chemical Shift of between 3.7 and 2.9 ppm. This can be achieved with superheated water having a temperature from 105 to 180 °C or with water containing certain salts. The process results in shaped polyamide articles with improved crystallinity and thus improved mechanical properties.
C08J 7/02 - Traitement chimique ou revêtement d'objets façonnés faits de substances macromoléculaires par des solvants, p. ex. par des agents gonflants
78.
METHOD FOR THE TREATMENT OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY IN NEWBORNS
The invention is in the field of medical treatments. It provides means and methods for treating acute or sub-acute brain injury due to asphyxia in newborns. It has now been found that hypoxic-ischemic encephalopathy may effectively be treated by administering a composition comprising Annexin A1 to a subject in need of such a treatment. The invention therefore relates to a treatment for hypoxic-ischemic encephalopathy in newborns by administering a composition comprising Annexin A1 to a preterm born newborn.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The invention relates to stents, in particular to a stent for insertion in a vein of a human or animal body. The invention also relates to a catheter stent insertion device for inserting a stent according to the invention in a vein of a human or animal body. The invention also relates to a method for inserting a stent according to the invention in a vein of a human or animal body using a catheter stent insertion device according to the invention.
A61F 2/82 - Dispositifs maintenant le passage ou évitant l’affaissement de structures tubulaires du corps, p. ex. stents
A61F 2/915 - Stents ayant une forme caractérisée par des éléments filiformesStents ayant une forme caractérisée par une structure de type filet ou de type à mailles caractérisés par une structure de type filet ou de type à mailles fabriquée à partir de feuilles perforées ou de tubes perforés, p. ex. perforés par découpe au laser ou gravés avec des bandes présentant une structure en méandre, des bandes adjacentes étant reliées l’une à l’autre
80.
SELECTIVE PDE4D INHIBITORS AGAINST DEMYELINATING DISEASES
The current invention relates to selective PDE4D inhibitors for use in the prevention and/or treatment of demyelinating diseases of the central nervous system and of the peripheral nervous system.
The present invention relates to an in vitro method for diagnosing a biliary tract disease in a subject by determining the concentration of one or more biomarkers in a biospecimen from the subject and comparing it to a reference biospecimen. The method is particularly suitable for diagnosing primary sclerosing cholangitis (PSC) and cholangiocarcinoma. The preferred detection method for the biomarkers is MALDI- MSI.
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
82.
APPARATUS FOR HANDLING A ROD SHAPED ELEMENT TO BE INSERTED INTO OR REMOVED FROM THE EYE OF A PATIENT
The invention relates to an apparatus for handling a rod shaped element to be inserted into or removed from an eye of a patient, the apparatus comprising tweezers having a pair of legs joined to one another at a first end, and a second end of each leg comprises a gripping element, wherein the gripping elements can be manually moved from a first spaced apart position to a second gripping position. The invention also relates to a system comprising such an apparatus and to the use of such an apparatus.
A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
A61B 17/04 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour la suture des plaiesSupports ou emballages pour aiguilles ou matériaux de suture
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
The invention is in the field of medical treatments and provides polypeptides for the treatment of inflammatory diseases. The invention also provides a method for the quantification of histone H4 such as a method for in vivo or in vitro imaging of atherosclerotic lesions using polypeptides. More in particular, the invention provides a polypeptide comprising an amino acid sequence according to SEQ ID NO: 1.
C40B 40/10 - Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
84.
Method for the treatment or prevention of osteoarthritis
The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.
The invention also relates to a MRI apparatus for obtaining images of a target volume of a human and/or animal subject using magnetic resonance imaging (MRI), said MRI apparatus at least comprising: a housing defining a target area for accommodating said human and/or animal subject; at least one main magnet unit and at least one magnetic gradient unit for applying - during use - one or more magnetic field gradients along three independent orthogonal spatial axes in said target area, as well as at least one radiofrequency (RF) pulse generation unit for applying one or more sets of RF pulses towards said target area; a RF receiving unit for acquiring MRI signals possibly having multi-channel spatially sensitive characteristics; and a computer processing unit for processing said acquired MRI signals and for producing said magnetic resonance image data.
G01R 33/561 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne par réduction du temps de balayage, c.-à-d. systèmes d'acquisition rapide, p. ex. utilisant des séquences d'impulsions écho-planar
G01R 33/565 - Correction de distorsions d'image, p. ex. dues à des inhomogénéités de champ magnétique
G01R 33/483 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p. ex. spectroscopie in vivo
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
G01R 33/28 - Détails des appareils prévus dans les groupes
86.
METHOD OF MAKING AN OSTEOCONDUCTIVE POLYMER ARTICLE AND AN OSTEOCONDUCTIVE POLYMER ARTICLE THUS MADE
The disclosure relates to methods of making an osteoconductive polymer article for use as an orthopedic implant comprises steps of forming an article from a biocompatible, non-biodegradable polymer, the article comprising a non-flat surface with roughness Ra of at least 5 µm; providing a dispersion of bioactive ceramic particles of particle size at most 10 µm in a first solvent comprising a solvent for the polymer; coating at least the non-flat surface with the dispersion in at least one step; and rinsing the coated article with a second solvent being a non-solvent for the polymer to substantially remove the first solvent. Further disclosed is an osteoconductive polymer article for use as an orthopedic implant, which article is made from a biocompatible, non-biodegradable polymer and comprises a non-flat surface with roughness Ra of at least 5 µm, wherein bioactive ceramic particles of particle size at most 10 µm are partly embedded in the polymer at the surface of the article. The methods exhibit benefits in ease of modifying a surface layer with bioactive particles, applying mild conditions and not requiring use of further additives or post- treatments, or without significantly affecting bulk polymer properties, and result in an orthopedic implant article having particles adhering to the surface while still being accessible for interaction with surrounding tissue or fluid.
A61L 27/44 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire
A61L 27/46 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire avec des charges inorganiques contenant du phosphore
A device (100) for detecting viral particles (132) includes a polymer material (112) over a substrate (110); a heat transfer element (114) thermally coupled to the substrate; a temperature modification device (118) thermally coupled to the heat transfer element; a controller (121) to produce a thermal (202) wave emanating from the heat transfer element; a flow cell (122) located and configured to pass a liquid (124) over the polymer material; a temperature sensor (134) to detect a temperature (T2) of the liquid passing over the polymer material; and a processor (123) to calculate a concentration of viral particles (132) in the liquid based at least in part on a phase shift between the thermal wave at the heat transfer element and an attenuated thermal wave (204) in the liquid. Related methods of forming such a device and detecting viral particles using said device and Thermal Wave Transport Anaysis (TWTA) are also disclosed.
2) of the liquid passing over the polymer material; and a processor (123) to calculate a concentration of an analyte (132) in the liquid based at least in part on a phase shift between the thermal wave at the heat transfer element and an attenuated thermal wave (204) in the liquid. Related methods of forming such a device and detecting analytes are also disclosed.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 25/18 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques en recherchant la conductivité thermique
G01N 25/20 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques en recherchant la production de quantités de chaleur, c.-à-d. la calorimétrie, p. ex. en mesurant la chaleur spécifique, en mesurant la conductivité thermique
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
89.
A DEVICE FOR SUPPORTING THE TESTING OF A BRACHYTHERAPY APPLICATOR AND A METHOD FOR TESTING OF SUCH A BRACHYTHERAPY APPLICATOR PRIOR TO THE USE OF THE BRACHYTHERAPY APPLICATOR IN BRACHYTHERAPY RADIATION TREATMENTS
The invention relates to a device for supporting the testing of a brachytherapy applicator prior to the use of the brachytherapy applicator in brachytherapy radiation treatments. The invention also relates to a method for testing of a brachytherapy applicator prior to the use of the brachytherapy applicator in brachytherapy radiation treatments.
Transapical heart port for insertion into a heart of a human or an animal subject, said transapical heart port comprising: a port housing (11) having a length dimension and a diameter dimension and comprising a first, proximal housing end and a housing second, distal housing end, wherein said port housing defines a housing channel extending along said length dimension between said first, proximal housing end and said second, distal housing end, wherein said port housing is configured to be inserted with said first, proximal housing end into a heart of a human or animal subject at the apex of said heart, whereas said second, distal housing end of said port housing is configured to remain outside said heart of a human or animal subject, wherein said housing channel is configured to provide repeated access to the interior of said housing heart through said housing channel, and wherein a hemostatic valve (25) attached to said housing and located within said channel, said hemostatic valve being configured to reduce blood loss from said heart through said channel, wherein said second, distal housing end comprises a securing portion (20) configured to secure said second, distal housing end to an exterior region of said heart, said securing portion being configured as a slab-like element of a flexible material extending away from said second, distal housing end, wherein said flexible slab-like element is arranged to be sutured to said exterior region of said heart.
The invention relates to stents, in particular to a stent for insertion in a vein of a human or animal body. The invention also relates to a catheter stent insertion device for inserting a stent according to the invention in a vein of a human or animal body. The invention also relates to a method for inserting a stent according to the invention in a vein of a human or animal body using a catheter stent insertion device according to the invention.
The invention relates to the radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. In particular the invention relates to an endorectal probe device for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. Furthermore the invention relates to an afterloading apparatus for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject using an endorectal probe device according to the invention. Moreover the invention relates to a method for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject, wherein the method implements the endorectal probe device according to the invention.
The invention relates to device for determining the chemical composition of a living eye comprising light emitting means for emitting a light beam; light guidance means having an entrance surface and an exit surface and arranged to be brought in optical contact with the eye for directing said light beam being emitted towards the eye, such that at least part of the eye is being illuminated with a light beam having an oblique angle of incidence with respect to the visual axis of the eye and for receiving and guiding at least a fraction of the light beam leaving the eye as a result of said illumination towards light detecting means for determining the chemical composition of said eye by analyzing said fraction of light. The invention also relates to an optical unit for implementation in such a device for performing measurements of the chemical composition of the anterior eye.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medical treatment services; Medical services; Medical care; Medical information; Medical examinations; Medical examination of individuals; Medical information retrieval services; Medical treatment services; Provision of medical services; Services for the provision of medical facilities; Services for the provision of medical facilities; Residential medical treatment services; Provision of medical information relating to poisons; Arranging of medical treatment; Conducting of medical examinations; Individual medical counseling services provided to patients; Medical services for the treatment of conditions of the human body; Medical services for the diagnosis of conditions of the human body; Medical analysis services for the diagnosis of cancer.
95.
ELECTROGRAM-BASED CONTROL OF CARDIAC RESYNCHRONIZATION THERAPY
In some examples, controlling delivery of CRT includes delivering ventricular pacing according to a sequence of different values of at least one of A-V delay or V-V delay, and acquiring one or more electrograms from respective vectors. For each of the different values of the delay, at least one of a QRS amplitude or a QRS area may be determined based on the one or more electrograms, and a target change in QRS amplitude or QRS area between adjacent ones of the values of the at least one of A-V delay or V-V delay of the sequence may be identified. In response to the identification of the target change, the implantable medical device may deliver the ventricular pacing at a value of the at least one of A-V delay or V-V delay determined based on the identification to provide CRT.
A61N 1/365 - Stimulateurs cardiaques commandés par un paramètre physiologique, p. ex. par le potentiel cardiaque
A61N 1/368 - Stimulateurs cardiaques commandés par un paramètre physiologique, p. ex. par le potentiel cardiaque comprenant plus d'une électrode coopérant avec différentes régions du cœur
96.
Electrogram-based control of cardiac resynchronization therapy
In some examples, controlling delivery of CRT includes delivering ventricular pacing according to a sequence of different values of at least one of A-V delay or V-V delay, and acquiring one or more electrograms from respective vectors. For each of the different values of the at least one of A-V delay or V-V delay, at least one of a QRS amplitude or a QRS area may be determined based on the one or more electrograms, and a target change in QRS amplitude or QRS area between adjacent ones of the values of the at least one of A-V delay or V-V delay of the sequence may be identified. In response to the identification of the target change, the implantable medical device may deliver the ventricular pacing at a value of the at least one of A-V delay or V-V delay determined based on the identification to provide CRT.
A61N 1/365 - Stimulateurs cardiaques commandés par un paramètre physiologique, p. ex. par le potentiel cardiaque
A61N 1/368 - Stimulateurs cardiaques commandés par un paramètre physiologique, p. ex. par le potentiel cardiaque comprenant plus d'une électrode coopérant avec différentes régions du cœur
A61N 1/372 - Aménagements en relation avec l'implantation des stimulateurs
A device (200) for detecting an analyte (132) includes a thermocouple (210) coated with an assay polymer (214). The assay polymer is formulated to bind to the analyte, and a heat transfer property of the assay polymer varies responsive to an amount of the analyte bound thereto. A method of forming a sensor includes coating a thermocouple with an assay polymer. A method for detecting an analyte includes passing a liquid containing an analyte adjacent a thermocouple coated with an assay polymer, binding an analyte to the assay polymer, detecting a temperature of the thermocouple, and calculating a concentration of the analyte in the liquid based at least in part on the heat transfer property of the assay polymer.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.
The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide consists of an amino acid sequence according to SEQ ID NO: 18 or an analogue thereof, wherein the analogue is a peptide consisting of an amino acid sequence according to formula 1 (SEQ ID NO: 29), or a fragment thereof wherein the fragment consists of at least 10 consecutive amino acids of SEQ ID NO: 18 or an amino acid sequence according to formula 1.
A device for detecting an analyte includes a thermocouple having an assay polymer over a surface of the thermocouple. The assay polymer is formulated to bind to the analyte, and a heat transfer property of the assay polymer varies responsive to an amount of the analyte bound thereto. A method of forming a sensor includes providing an assay polymer over a thermocouple. A method for detecting an analyte includes passing a liquid containing an analyte adjacent a thermocouple having an assay polymer over a surface thereof, binding an analyte to the assay polymer, detecting a temperature of the thermocouple, and calculating a concentration of the analyte in the liquid based at least in part on the heat transfer property of the assay polymer.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 25/48 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques en recherchant la production de quantités de chaleur, c.-à-d. la calorimétrie, p. ex. en mesurant la chaleur spécifique, en mesurant la conductivité thermique sur une solution, sorption ou réaction chimique n'impliquant pas une oxydation par combustion ou catalyse
